Kymera Therapeutics (NASDAQ:KYMR) Stock Price Up 13.8% – Time to Buy?

Kymera Therapeutics, Inc. (NASDAQ:KYMR)’s stock price traded up 13.8% during trading on Monday . The stock traded as high as $98.00 and last traded at $102.9250. 138,930 shares traded hands during trading, a decline of 79% from the average session volume of 664,267 shares. The stock had previously closed at $90.43.

Key Kymera Therapeutics News

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera’s last reported quarter beat expectations, with EPS of ($0.71) versus the ($0.89) consensus and revenue of $34.37 million versus $8.27 million, reinforcing confidence in the business outlook.
• Positive Sentiment: A Zacks note said KYMR shares surged in the prior session on above-average volume, with recent earnings-estimate revisions suggesting there may be additional upside near term. Article Title
• Neutral Sentiment: Several insider transactions were disclosed under pre-arranged Rule 10b5-1 plans, which often makes them less concerning as a signal about near-term fundamentals.
• Negative Sentiment: Director Bruce Booth sold multiple large blocks of shares, including a $24.3 million sale and additional recent sales, and insider Noah Goodman also sold shares. While these were planned transactions, the volume and frequency can weigh on sentiment. Article Title

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KYMR. Wall Street Zen raised Kymera Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 2nd. Piper Sandler upped their price objective on Kymera Therapeutics from $125.00 to $140.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Citigroup increased their target price on Kymera Therapeutics from $110.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Stephens raised their target price on Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research note on Monday, March 2nd. Finally, Canaccord Genuity Group started coverage on shares of Kymera Therapeutics in a report on Wednesday, May 6th. They set a “buy” rating and a $106.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $117.14.

Kymera Therapeutics Price Performance

The stock has a fifty day moving average price of $83.67 and a two-hundred day moving average price of $81.54. The company has a market cap of $8.08 billion, a P/E ratio of -27.52 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period in the previous year, the firm posted ($0.82) earnings per share. The business’s revenue was up 55.5% on a year-over-year basis. As a group, analysts forecast that Kymera Therapeutics, Inc. will post -3.25 earnings per share for the current year.

Insider Activity

In other Kymera Therapeutics news, COO Jeremy G. Chadwick sold 4,279 shares of the business’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $81.58, for a total transaction of $349,080.82. Following the completion of the transaction, the chief operating officer owned 44,018 shares in the company, valued at approximately $3,590,988.44. The trade was a 8.86% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Elena Ridloff sold 3,000 shares of Kymera Therapeutics stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $87.00, for a total transaction of $261,000.00. Following the sale, the director owned 3,000 shares in the company, valued at approximately $261,000. This represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 630,876 shares of company stock worth $58,863,238 over the last ninety days. 15.98% of the stock is currently owned by company insiders.

Institutional Trading of Kymera Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Empowered Funds LLC acquired a new position in shares of Kymera Therapeutics during the first quarter valued at approximately $203,000. Glenmede Trust Co. NA raised its stake in shares of Kymera Therapeutics by 3.6% in the 1st quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock worth $565,000 after buying an additional 235 shares in the last quarter. Amundi bought a new stake in shares of Kymera Therapeutics in the 1st quarter worth $249,000. California State Teachers Retirement System lifted its holdings in shares of Kymera Therapeutics by 23.0% in the first quarter. California State Teachers Retirement System now owns 56,282 shares of the company’s stock valued at $4,688,000 after buying an additional 10,540 shares during the period. Finally, Eagle Health Investments LP boosted its stake in Kymera Therapeutics by 7.0% during the first quarter. Eagle Health Investments LP now owns 145,816 shares of the company’s stock valued at $12,145,000 after buying an additional 9,516 shares in the last quarter.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.